As antigens suitable for targeting the AML-LIC are commonly shared by healthy HSPCs and myeloid progenitors, myeloablation is inevitable and therefore we evaluated whether CAR T cells targeting CD117 would eliminate HSPCs in vivo. The gene discussed is KIT; the disease is acute myeloid leukemia.